[Intestinal cryptosporidiosis in HIV infection: clinical features, course and therapy].
OBJECTIVE
To determine retrospectively the clinical features and course of HIV-associated intestinal Cryptosporidium infection and its response to paromomycin.


METHODS
Case notes of all patients treated for cryptosporidiosis over a two-year period at an HIV out-patient clinic were analysed (26 men, four women; median CD4-lymphocyte count: 20/microliter). Median follow-up time was 6(1-22) months.


RESULTS
15 patients had persistent diarrhoea, two remained asymptomatic, seven had a remission and in five the disease took a fulminant course with severe diarrhoea ending in death within 4 months. 15 of the patients died during the period of observation, eight of them of cryptosporidiosis-associated cachexia. Mean survival time was about one year. Eight patients had multiple intestinal infections at the time the diagnosis was made and seven developed them later, which correlated with the poorer survival chances. Four patients had proven and 13 probably cryptosporidiosis-associated involvement of the biliary tract, but this did not affect the survival chances. 21 of 28 patients with diarrhoea were treated with paromomycin. In 13 of them there was for a time complete or partial response to treatment, but no response in eight. Those who responded well or partially to paromomycin had a significantly better survival chance than those without response. There was no correlation between the severity of immunosuppression and the severity of the cryptosporidiosis-associated diarrhoea, the response to paromomycin and the worse survival chance in the presence of multiple intestinal infections.


CONCLUSIONS
The reasons for the different courses taken by HIV-associated cryptosporidiosis and the different therapeutic responses remain unclear. There is no known causal treatment, but 60% of patients improved temporarily on paromomycin.
Günthard
M
M
Abteilung infektionskrankheiten und Spitalhygiene, Universitätsspital Zürich.
Meister
T
T
Lüthy
R
R
Weber
R
R
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003457:Cryptosporidiosis / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010303:Paromomycin / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors
D000900:Anti-Bacterial Agents; D010303:Paromomycin
Intestinale Kryptosporidiose bei HIV-Infektion. Krankheitsbild, Verlauf und Therapie.